

Anthony J Rothschild

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2827085/publications.pdf>

Version: 2024-02-01

174
papers

7,140
citations

57758

44
h-index

66911

78
g-index

179
all docs

179
docs citations

179
times ranked

5726
citing authors

#	ARTICLE	IF	CITATIONS
1	Subcallosal cingulate deep brain stimulation for treatment-resistant depression: a multisite, randomised, sham-controlled trial. <i>Lancet Psychiatry</i> , 2017, 4, 839-849.	7.4	382
2	A Review of Postpartum Psychosis. <i>Journal of Women's Health</i> , 2006, 15, 352-368.	3.3	345
3	An open label trial of C-1073 (mifepristone) for psychotic major depression*. <i>Biological Psychiatry</i> , 2002, 52, 386-392.	1.3	302
4	Psychotic (delusional) major depression: should it be included as a distinct syndrome in DSM-IV?. <i>American Journal of Psychiatry</i> , 1992, 149, 733-745.	7.2	286
5	Demonstration of the Efficacy and Safety of a Novel Substance P (NK1) Receptor Antagonist in Major Depression. <i>Neuropsychopharmacology</i> , 2004, 29, 385-392.	5.4	268
6	A corticosteroid/dopamine hypothesis for psychotic depression and related states. <i>Journal of Psychiatric Research</i> , 1985, 19, 57-64.	3.1	232
7	Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study. <i>Journal of Psychiatric Research</i> , 2019, 111, 59-67.	3.1	197
8	Neuropsychological Deficits in Psychotic Versus Nonpsychotic Major Depression and No Mental Illness. <i>American Journal of Psychiatry</i> , 2000, 157, 1095-1100.	7.2	192
9	A Double-blind Randomized Controlled Trial of Olanzapine Plus Sertraline vs Olanzapine Plus Placebo for Psychotic Depression. <i>Archives of General Psychiatry</i> , 2009, 66, 838.	12.3	188
10	Trial of SAGE-217 in Patients with Major Depressive Disorder. <i>New England Journal of Medicine</i> , 2019, 381, 903-911.	27.0	156
11	The dexamethasone suppression test: identification of subtypes of depression. <i>American Journal of Psychiatry</i> , 1983, 140, 88-91.	7.2	146
12	Selective serotonin reuptake inhibitor-induced sexual dysfunction: efficacy of a drug holiday. <i>American Journal of Psychiatry</i> , 1995, 152, 1514-1516.	7.2	138
13	A Double-Blind, Randomized Study of Olanzapine and Olanzapine/Fluoxetine Combination for Major Depression With Psychotic Features. <i>Journal of Clinical Psychopharmacology</i> , 2004, 24, 365-373.	1.4	128
14	Loss of Antidepressant Efficacy During Maintenance Therapy. <i>Journal of Clinical Psychiatry</i> , 1998, 59, 279-288.	2.2	122
15	GABAergic neuroactive steroids and resting-state functional connectivity in postpartum depression: A preliminary study. <i>Journal of Psychiatric Research</i> , 2013, 47, 816-828.	3.1	114
16	Olanzapine and haloperidol in first episode psychosis: Two-year data. <i>Schizophrenia Research</i> , 2006, 86, 234-243.	2.0	112
17	Basal ganglia choline levels in depression and response to fluoxetine treatment: An in vivo proton magnetic resonance spectroscopy study. <i>Biological Psychiatry</i> , 1997, 41, 837-843.	1.3	107
18	The effects of a single acute dose of dexamethasone on monoamine and metabolite levels in rat brain. <i>Life Sciences</i> , 1985, 36, 2491-2501.	4.3	100

#	ARTICLE	IF	CITATIONS
19	The Prevention of Recurrent Episodes of Depression With Venlafaxine for Two Years (PREVENT) Study. <i>Journal of Clinical Psychiatry</i> , 2007, 68, 1246-1256.	2.2	93
20	Reexposure to fluoxetine after serious suicide attempts by three patients: the role of akathisia. <i>Journal of Clinical Psychiatry</i> , 1991, 52, 491-3.	2.2	92
21	Relationships between brain ct scan findings and cortisol in psychotic and nonpsychotic depressed patients. <i>Biological Psychiatry</i> , 1989, 26, 565-575.	1.3	91
22	Challenges in the treatment of depression with psychotic features. <i>Biological Psychiatry</i> , 2003, 53, 680-690.	1.3	89
23	Abnormal Results of Dexamethasone Suppression Tests in Nondepressed Patients With Diabetes Mellitus. <i>Archives of General Psychiatry</i> , 1984, 41, 1086.	12.3	88
24	Clinical Predictors of Acute Response With Quetiapine in Psychotic Mood Disorders. <i>Journal of Clinical Psychiatry</i> , 2000, 61, 185-189.	2.2	87
25	Challenges in the Treatment of Major Depressive Disorder With Psychotic Features. <i>Schizophrenia Bulletin</i> , 2013, 39, 787-796.	4.3	81
26	Peripartum neuroactive steroid and β -aminobutyric acid profiles in women at-risk for postpartum depression. <i>Psychoneuroendocrinology</i> , 2016, 70, 98-107.	2.7	79
27	Effects of Antipsychotic Medication on Brain Structure in Patients With Major Depressive Disorder and Psychotic Features. <i>JAMA Psychiatry</i> , 2020, 77, 674.	11.0	76
28	Olanzapine Response in Psychotic Depression. <i>Journal of Clinical Psychiatry</i> , 1999, 60, 116-118.	2.2	73
29	The Dexamethasone Suppression Test as a Discriminator among Subtypes of Psychotic Patients. <i>British Journal of Psychiatry</i> , 1982, 141, 471-474.	2.8	72
30	Dexamethasone increases plasma free dopamine in man. <i>Journal of Psychiatric Research</i> , 1984, 18, 217-223.	3.1	68
31	Missed Diagnosis of Psychotic Depression at 4 Academic Medical Centers. <i>Journal of Clinical Psychiatry</i> , 2008, 69, 1293-1296.	2.2	68
32	Antidepressant Augmentation Using the <i>N</i> -Methyl-D-Aspartate Antagonist Memantine. <i>Journal of Clinical Psychiatry</i> , 2013, 74, 966-973.	2.2	67
33	Efficacy of the combination of fluoxetine and perphenazine in the treatment of psychotic depression. <i>Journal of Clinical Psychiatry</i> , 1993, 54, 338-42.	2.2	62
34	Does psychosis increase the risk of suicide in patients with major depression? A systematic review. <i>Journal of Affective Disorders</i> , 2016, 198, 23-31.	4.1	61
35	Resting-state functional connectivity, cortical GABA, and neuroactive steroids in peripartum and peripartum depressed women: a functional magnetic resonance imaging and spectroscopy study. <i>Neuropsychopharmacology</i> , 2019, 44, 546-554.	5.4	57
36	Psychotic and nonpsychotic depressions: I. comparisons of plasma catecholamines and cortisol measures. <i>Psychiatry Research</i> , 1987, 20, 143-153.	3.3	56

#	ARTICLE	IF	CITATIONS
37	The relationship between change in apathy and changes in cognition and functional outcomes in currently non-depressed SSRI-treated patients with major depressive disorder. <i>Comprehensive Psychiatry</i> , 2014, 55, 1-10.	3.1	55
38	The dexamethasone suppression test in normal control subjects: comparison of two assays and effect of age. <i>American Journal of Psychiatry</i> , 1984, 141, 1550-1555.	7.2	54
39	Effect of Continuing Olanzapine vs Placebo on Relapse Among Patients With Psychotic Depression in Remission. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 622.	7.4	53
40	Prevention of Recurrent Episodes of Depression With Venlafaxine ER in a 1-Year Maintenance Phase From the PREVENT Study. <i>Journal of Clinical Psychiatry</i> , 2007, 68, 1014-1023.	2.2	53
41	Risk factors for suicide among 34,671 patients with psychotic and non-psychotic severe depression. <i>Journal of Affective Disorders</i> , 2014, 156, 119-125.	4.1	50
42	The treatment of psychotic depression: Is there consensus among guidelines and psychiatrists?. <i>Journal of Affective Disorders</i> , 2013, 145, 214-220.	4.1	48
43	McLean Hospital Depression Research Facility: early-onset phobic disorders and adult-onset major depression. <i>British Journal of Psychiatry</i> , 1998, 173, 29-34.	2.8	47
44	Vitamin D supplementation in bipolar depression: A double blind placebo controlled trial. <i>Journal of Psychiatric Research</i> , 2017, 95, 48-53.	3.1	47
45	Vortioxetine (Lu AA21004) 5 mg in generalized anxiety disorder: Results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States. <i>European Neuropsychopharmacology</i> , 2012, 22, 858-866.	0.7	46
46	Impact of Pharmacogenomics on Clinical Outcomes for Patients Taking Medications With Gene-Drug Interactions in a Randomized Controlled Trial. <i>Journal of Clinical Psychiatry</i> , 2019, 80, .	2.2	45
47	The Roles of Glucocorticoid and Dopaminergic Systems in Delusional (Psychotic) Depression. <i>Annals of the New York Academy of Sciences</i> , 1988, 537, 462-471.	3.8	40
48	Correlation between patient and clinician assessments of depression severity in the PREVENT study. <i>Psychiatry Research</i> , 2010, 177, 177-183.	3.3	40
49	Persisting Low Use of Antipsychotics in the Treatment of Major Depressive Disorder With Psychotic Features. <i>Journal of Clinical Psychiatry</i> , 2007, 68, 194-200.	2.2	40
50	The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the Acute and Continuation Phases. <i>Biological Psychiatry</i> , 2007, 62, 1371-1379.	1.3	39
51	Relationships Between Multiple Sclerosis and Depression. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2011, 23, 198-200.	1.8	39
52	Concordance between clinician and patient ratings as predictors of response, remission, and recurrence in major depressive disorder. <i>Journal of Psychiatric Research</i> , 2011, 45, 96-103.	3.1	39
53	MANAGEMENT OF PSYCHOTIC, TREATMENT-RESISTANT DEPRESSION. <i>Psychiatric Clinics of North America</i> , 1996, 19, 237-252.	1.3	37
54	New directions in the treatment of antidepressant-induced sexual dysfunction. <i>Clinical Therapeutics</i> , 2000, 22, A42-A61.	2.5	37

#	ARTICLE	IF	CITATIONS
55	Considerations on the ICD-11 Classification of Psychotic Depression. <i>Psychotherapy and Psychosomatics</i> , 2012, 81, 135-144.	8.8	37
56	Comparison of the Frequency of Behavioral Disinhibition on Alprazolam, Clonazepam, or No Benzodiazepine in Hospitalized Psychiatric Patients. <i>Journal of Clinical Psychopharmacology</i> , 2000, 20, 7-11.	1.4	37
57	Hypothalamic-pituitary-adrenal axis activity and 1-year outcome in depression. <i>Biological Psychiatry</i> , 1993, 34, 392-400.	1.3	35
58	A Delusion Assessment Scale for Psychotic Major Depression: Reliability, Validity, and Utility. <i>Biological Psychiatry</i> , 2006, 60, 1336-1342.	1.3	35
59	Correlates of Suicidality Among Patients with Psychotic Depression. <i>Suicide and Life-Threatening Behavior</i> , 2008, 38, 403-414.	1.9	35
60	Effect of Age on the Frequency of Anxiety Disorders in Major Depression With Psychotic Features. <i>American Journal of Geriatric Psychiatry</i> , 2010, 18, 404-412.	1.2	35
61	Measuring psychotic depression. <i>Acta Psychiatrica Scandinavica</i> , 2014, 129, 211-220.	4.5	35
62	Psychosocial outcomes in patients with recurrent major depressive disorder during 2years of maintenance treatment with venlafaxine extended release. <i>Journal of Affective Disorders</i> , 2010, 126, 420-429.	4.1	34
63	Polypharmacy prevalence rates in the treatment of unipolar depression in an outpatient clinic. <i>Journal of Affective Disorders</i> , 2009, 117, 18-23.	4.1	31
64	Influence of Sex and Menopausal Status on Response, Remission, and Recurrence in Patients With Recurrent Major Depressive Disorder Treated With Venlafaxine Extended Release or Fluoxetine. <i>Journal of Clinical Psychiatry</i> , 2014, 75, 62-68.	2.2	31
65	How Long Should Patients With Psychotic Depression Stay on the Antipsychotic Medication?. <i>Journal of Clinical Psychiatry</i> , 2003, 64, 390-396.	2.2	31
66	Measuring treatment response in psychotic depression: The Psychotic Depression Assessment Scale (PDAS) takes both depressive and psychotic symptoms into account. <i>Journal of Affective Disorders</i> , 2014, 160, 68-73.	4.1	29
67	The association between latent depression subtypes and remission after treatment with citalopram: A latent class analysis with distal outcome. <i>Journal of Affective Disorders</i> , 2015, 188, 270-277.	4.1	29
68	Depression and cognitive impairment among newly admitted nursing home residents in the USA. <i>International Journal of Geriatric Psychiatry</i> , 2017, 32, 1172-1181.	2.7	29
69	Symptom severity of bipolar disorder during the menopausal transition. <i>International Journal of Bipolar Disorders</i> , 2015, 3, 35.	2.2	28
70	<p>Durability of symptomatic responses obtained with adjunctive vagus nerve stimulation in treatment-resistant depression</p>. <i>Neuropsychiatric Disease and Treatment</i> , 2019, Volume 15, 457-468.	2.2	28
71	Sustaining remission of psychotic depression: rationale, design and methodology of STOP-PD [†] [†] . <i>BMC Psychiatry</i> , 2013, 13, 38.	2.6	27
72	White matter integrity in medication-free women with peripartum depression: a tract-based spatial statistics study. <i>Neuropsychopharmacology</i> , 2018, 43, 1573-1580.	5.4	27

#	ARTICLE	IF	CITATIONS
73	Gas-phase pyrolysis of phenyltrimethylsilyldiazomethane. Intramolecular chemistry of phenyltrimethylsilylcarbene. <i>Journal of the American Chemical Society</i> , 1977, 99, 6995-6999.	13.7	26
74	Psychiatric outcomes following medical and surgical abortion. <i>Human Reproduction</i> , 2007, 22, 878-884.	0.9	26
75	Vagus Nerve Stimulation and Food Intake. <i>Journal of Diabetes Science and Technology</i> , 2014, 8, 590-595.	2.2	26
76	Platelet MAO activity and the dexamethasone suppression test in depressed patients. <i>American Journal of Psychiatry</i> , 1983, 140, 1231-1233.	7.2	25
77	Changes in Depression Subtypes Among Men in STAR*D: A Latent Transition Analysis. <i>American Journal of Men's Health</i> , 2018, 12, 5-13.	1.6	25
78	Clinical and psychometric validation of the psychotic depression assessment scale. <i>Journal of Affective Disorders</i> , 2015, 173, 261-268.	4.1	24
79	Progression of female reproductive stages associated with bipolar illness exacerbation. <i>Bipolar Disorders</i> , 2012, 14, 515-526.	1.9	23
80	Sexual side effects of antidepressants. <i>Journal of Clinical Psychiatry</i> , 2000, 61 Suppl 11, 28-36.	2.2	23
81	Depression Secondary to Anxiety: Findings from the McLean Hospital Depression Research Facility. <i>Psychiatric Clinics of North America</i> , 1990, 13, 633-649.	1.3	22
82	Psychiatrists' responses to failure of maintenance therapy with antidepressants. <i>Psychiatric Services</i> , 1997, 48, 835-837.	2.0	22
83	Biology of Depression. <i>Medical Clinics of North America</i> , 1988, 72, 765-790.	2.5	20
84	Delusional depression, family history, and DST response: A pilot study. <i>Biological Psychiatry</i> , 1986, 21, 1239-1246.	1.3	19
85	Psychotic and nonpsychotic depressions: II. platelet MAO activity, plasma catecholamines, cortisol, and specific symptoms. <i>Psychiatry Research</i> , 1987, 20, 155-164.	3.3	19
86	Sexual Functioning in Patients With Recurrent Major Depressive Disorder Enrolled in the PREVENT Study. <i>Journal of Nervous and Mental Disease</i> , 2013, 201, 266-273.	1.0	19
87	Selective Serotonin Reuptake Inhibitors and Delusional Depression. <i>American Journal of Psychiatry</i> , 1999, 156, 977a-978.	7.2	19
88	Mania After Withdrawal of Isocarboxazid. <i>Journal of Clinical Psychopharmacology</i> , 1985, 5, 340-342.	1.4	18
89	Comparing sensitivity to change using the 6-item versus the 17-item Hamilton depression rating scale in the GUIDED randomized controlled trial. <i>BMC Psychiatry</i> , 2019, 19, 420.	2.6	18
90	Combinatorial Pharmacogenomic Algorithm is Predictive of Citalopram and Escitalopram Metabolism in Patients with Major Depressive Disorder. <i>Psychiatry Research</i> , 2020, 290, 113017.	3.3	18

#	ARTICLE	IF	CITATIONS
91	Impact of prior pharmacotherapy on remission of psychotic depression in a randomized controlled trial. <i>Journal of Psychiatric Research</i> , 2011, 45, 896-901.	3.1	17
92	Rating scales measuring the severity of psychotic depression. <i>Acta Psychiatrica Scandinavica</i> , 2015, 132, 335-344.	4.5	17
93	Structural brain networks in remitted psychotic depression. <i>Neuropsychopharmacology</i> , 2020, 45, 1223-1231.	5.4	17
94	Depression symptoms and cognitive impairment in older nursing home residents in the <scp>USA</scp>: A latent class analysis. <i>International Journal of Geriatric Psychiatry</i> , 2020, 35, 769-778.	2.7	17
95	A Gender Analysis of the Study of Pharmacotherapy of Psychotic Depression (STOP-PD). <i>Journal of Clinical Psychiatry</i> , 2013, 74, 1003-1009.	2.2	16
96	Toward a Biochemical Classification of Depressive Disorders IX. <i>British Journal of Psychiatry</i> , 1985, 146, 633-637.	2.8	15
97	Weight gain during olanzapine treatment for psychotic depression: effects of dose and age. <i>International Clinical Psychopharmacology</i> , 2008, 23, 130-137.	1.7	15
98	Alleged intermediacy of a silacyclopropane in the pyrolysis of phenyltrimethylsilyldiazomethane. <i>Journal of the American Chemical Society</i> , 1975, 97, 657-658.	13.7	14
99	Factors associated with non-completion in a double-blind randomized controlled trial of olanzapine plus sertraline versus olanzapine plus placebo for psychotic depression. <i>Psychiatry Research</i> , 2012, 197, 221-226.	3.3	14
100	The Impact of Sertraline Co-Administration on the Pharmacokinetics of Olanzapine: A Population Pharmacokinetic Analysis of the STOP-PD. <i>Clinical Pharmacokinetics</i> , 2015, 54, 1161-1168.	3.5	14
101	Cortisol response to the Trier Social Stress Test in pregnant women at risk for postpartum depression. <i>Archives of Women's Mental Health</i> , 2016, 19, 789-797.	2.6	14
102	Establishing the cut-off score for remission and severity-ranges on the Psychotic Depression Assessment Scale (PDAS). <i>Journal of Affective Disorders</i> , 2016, 190, 111-114.	4.1	14
103	Fluctuating postdexamethasone cortisol levels in a patient with melancholia. <i>American Journal of Psychiatry</i> , 1982, 139, 129-130.	7.2	13
104	Effect of Sertraline on Risk of Falling in Older Adults with Psychotic Depression on Olanzapine: Results of a Randomized Placebo-Controlled Trial. <i>American Journal of Geriatric Psychiatry</i> , 2014, 22, 332-336.	1.2	13
105	Improvement in Depression is Associated with Improvement in Cognition in Late-Life Psychotic Depression. <i>American Journal of Geriatric Psychiatry</i> , 2017, 25, 672-679.	1.2	13
106	Combinatorial Pharmacogenomic Testing Improves Outcomes for Older Adults With Depression. <i>American Journal of Geriatric Psychiatry</i> , 2020, 28, 933-945.	1.2	13
107	The Role of Dopamine in Psychotic Depression. <i>Clinical Neuropharmacology</i> , 1995, 18, S66-S73.	0.7	12
108	Treatment of Antidepressant-Induced Sexual Dysfunction. <i>Hospital Practice (1995)</i> , 1999, 34, 89-96.	1.0	12

#	ARTICLE	IF	CITATIONS
109	The Rothschild Scale for Antidepressant Tachyphylaxis: reliability and validity. <i>Comprehensive Psychiatry</i> , 2008, 49, 508-513.	3.1	12
110	Relationship Between Cerebrovascular Risk, Cognition, and Treatment Outcome in Late-Life Psychotic Depression. <i>American Journal of Geriatric Psychiatry</i> , 2015, 23, 1270-1275.	1.2	10
111	Changes in depression subtypes for women during treatment with citalopram: a latent transition analysis. <i>Archives of Women's Mental Health</i> , 2016, 19, 769-778.	2.6	10
112	Resting state functional connectivity in patients with remitted psychotic depression: A multi-centre STOP-PD study. <i>EBioMedicine</i> , 2018, 36, 446-453.	6.1	10
113	Impaired Insight Into Delusions Predicts Treatment Outcome During a Randomized Controlled Trial for Psychotic Depression (STOP-PD Study). <i>Journal of Clinical Psychiatry</i> , 2015, 76, 427-433.	2.2	10
114	Rethinking the classification of mixed affective episodes in ICD-11. <i>Journal of Affective Disorders</i> , 2012, 138, 170-172.	4.1	9
115	The Incidence of Tardive Dyskinesia in the Study of Pharmacotherapy for Psychotic Depression. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 391-397.	1.4	9
116	Persistent delusional theme over 13 episodes of psychotic depression. <i>Acta Neuropsychiatrica</i> , 2013, 25, 370-373.	2.1	9
117	SSRI+antipsychotic combination in psychotic depression: sertraline pharmacokinetics in the presence of olanzapine, a brief report from the STOP-PD study. <i>Human Psychopharmacology</i> , 2016, 31, 252-255.	1.5	9
118	Functional Impairment and Changes in Depression Subtypes for Women in STAR*D: A Latent Transition Analysis. <i>Journal of Women's Health</i> , 2016, 25, 464-472.	3.3	9
119	The Dexamethasone Suppression Test in Psychiatric Disorders. <i>Psychiatric Annals</i> , 1993, 23, 662-670.	0.1	9
120	The Association of Baseline Suicidality With Treatment Outcome in Psychotic Depression. <i>Journal of Clinical Psychiatry</i> , 2017, 78, 1149-1154.	2.2	9
121	Clinical validation of combinatorial pharmacogenomic testing and single-gene guidelines in predicting psychotropic medication blood levels and clinical outcomes in patients with depression. <i>Psychiatry Research</i> , 2021, 296, 113649.	3.3	8
122	Does major depressive disorder with somatic delusions constitute a distinct subtype of major depressive disorder with psychotic features?. <i>Journal of Affective Disorders</i> , 2009, 112, 250-255.	4.1	7
123	The Pitfalls of Psychotropic Polypharmacy. <i>Journal of Clinical Psychopharmacology</i> , 2021, 41, 227-232.	1.4	7
124	The diagnosis and treatment of late-life depression. <i>Journal of Clinical Psychiatry</i> , 1996, 57 Suppl 5, 5-11.	2.2	7
125	Mania After Withdrawal of Isocarboxazid. <i>Journal of Clinical Psychopharmacology</i> , 1985, 5, 340-342.	1.4	6
126	Stabilization treatment of remitted psychotic depression: the STOP-PD study. <i>Acta Psychiatrica Scandinavica</i> , 2018, 138, 267-273.	4.5	6

#	ARTICLE	IF	CITATIONS
127	Triazolam and disinhibition. <i>Lancet, The</i> , 1993, 341, 186.	13.7	5
128	Advances in the management of depression: Implications for the obstetrician/gynecologist. <i>American Journal of Obstetrics and Gynecology</i> , 1995, 173, 659-666.	1.3	5
129	Psychotic depression and suicide. <i>Acta Psychiatrica Scandinavica</i> , 2018, 137, 364-365.	4.5	5
130	Changes in depressive symptoms and cognitive impairment in older long-stay nursing home residents in the USA: a latent transition analysis. <i>Aging and Mental Health</i> , 2020, 25, 1-10.	2.8	5
131	Pharmacotherapy Prescriptions for Relapse Prevention of Psychotic Depression After Electroconvulsive Therapy. <i>Journal of Clinical Psychopharmacology</i> , 2021, 41, 196-199.	1.4	5
132	The implications of the National Institute of Mental Health Research Domain Criteria for researchers and clinicians. <i>Acta Psychiatrica Scandinavica</i> , 2014, 130, 409-414.	4.5	4
133	Differential impact of anxiety symptoms and anxiety disorders on treatment outcome for psychotic depression in the STOP-PD study. <i>Comprehensive Psychiatry</i> , 2014, 55, 1069-1076.	3.1	4
134	Why Is There No Food and Drug Administration-Approved Medication for Major Depression With Psychotic Features?. <i>Journal of Clinical Psychopharmacology</i> , 2021, 41, 359-361.	1.4	4
135	Benzodiazepines Do Not Cause Suicide or Suicide Attempts. primary care companion for CNS disorders, <i>The</i> , 2017, 19, .	0.6	4
136	Assessing rates and predictors of tachyphylaxis during the prevention of recurrent episodes of depression with venlafaxine ER for two years (PREVENT) study. <i>Psychopharmacology Bulletin</i> , 2009, 42, 5-20.	0.0	4
137	Combinatorial pharmacogenomic algorithm is predictive of sertraline metabolism in patients with major depressive disorder. <i>Psychiatry Research</i> , 2022, 308, 114354.	3.3	4
138	Health-related quality of life in remitted psychotic depression. <i>Journal of Affective Disorders</i> , 2019, 256, 373-379.	4.1	3
139	A Blood Test for Depression?. <i>Journal of Clinical Psychiatry</i> , 2015, 76, e218-e219.	2.2	3
140	Factor analysis of the CORE measure of psychomotor disturbance in psychotic depression: Findings from the STOP-PD II study. <i>Psychiatry Research</i> , 2022, 314, 114648.	3.3	3
141	Manic episode after total abdominal hysterectomy with bilateral salpingo-oophorectomy. <i>Menopause</i> , 2012, 19, 476-478.	2.0	2
142	Effect of Older vs Younger Age on Anthropometric and Metabolic Variables During Treatment of Psychotic Depression With Sertraline Plus Olanzapine: The STOP-PD II Study. <i>American Journal of Geriatric Psychiatry</i> , 2020, 29, 645-654.	1.2	2
143	Association between psychomotor disturbance and treatment outcome in psychotic depression: a STOP-PD II report. <i>Psychological Medicine</i> , 2022, 52, 3957-3963.	4.5	2
144	A Dynamic Algorithm for the Treatment of Psychotic Major Depression. <i>Psychiatric Annals</i> , 2002, 32, 681-691.	0.1	2

#	ARTICLE	IF	CITATIONS
145	Placebo Response in Psychotic Depression. Journal of Clinical Psychiatry, 2005, 66, 1615.	2.2	2
146	Conflict-of-Interest Charge. American Journal of Psychiatry, 2004, 161, 1721-a-1722.	7.2	1
147	Psychosis in Major Depression. , 0, , 156-194.		1
148	Treatment for Major Depression With Psychotic Features (Psychotic Depression). Focus (American Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.8	1
149	O21. Resting-State Functional Connectivity, Cortical Gaba and Allopregnanolone in Postpartum Depression: AÄFunctional Magnetic Imaging and Spectroscopy Study. Biological Psychiatry, 2019, 85, S114.	1.3	1
150	Advances in the Treatment of Psychotic Depression. Current Treatment Options in Psychiatry, 2019, 6, 64-74.	1.9	1
151	Response to: Goldberg et al. and Severance et al. Letters to the Editor: The clinical significance of improving remission over standard of care â€œ The reality of treatment resistant-based therapies. Journal of Psychiatric Research, 2019, 114, 211-213.	3.1	1
152	Characteristics of Working-Age Adults With Schizophrenia Newly Admitted to Nursing Homes. Journal of the American Medical Directors Association, 2022, 23, 1227-1235.e3.	2.5	1
153	Dr. Schatzberg and Dr. Rothschild Reply. American Journal of Psychiatry, 1993, 150, 1131-1131.	7.2	0
154	Dr. Rothschild Replies. American Journal of Psychiatry, 1996, 153, 1371-1371.	7.2	0
155	On Psychotic Major Depression. American Journal of Psychiatry, 1996, 153, 847-847.	7.2	0
156	Neuroendocrinology of Mood Disorders. , 0, , 757-776.		0
157	The Relationships Between Vascular Risk, Cognition and Outcome in Late-Life Psychotic Depression. American Journal of Geriatric Psychiatry, 2015, 23, S102-S103.	1.2	0
158	The Association of Baseline Suicidality with Treatment Outcome in Psychotic Depression. American Journal of Geriatric Psychiatry, 2016, 24, S103-S104.	1.2	0
159	949. Replicated Aberrant Default Mode Resting State Functional Connectivity in Patients with Remitted Psychotic Depression. Biological Psychiatry, 2017, 81, S384.	1.3	0
160	943. White Matter Integrity in Medication-Free Women with Peripartum Depression: Diffusion Tensor Imaging Study Using Tract-Based Spatial Statistics. Biological Psychiatry, 2017, 81, S381-S382.	1.3	0
161	69. Neuroactive Steroids and GABA in Peripartum Depression. Biological Psychiatry, 2017, 81, S28-S29.	1.3	0
162	Continuation Treatment of Remitted Psychotic Depression: The STOP-PD Study. American Journal of Geriatric Psychiatry, 2018, 26, S86-S87.	1.2	0

#	ARTICLE	IF	CITATIONS
163	O46. SAGE-217 a First in Class GABAA Receptor Positive Allosteric Modulator in Major Depressive Disorder: A Multicenter, Randomized, Double-Blind, Phase 2 Placebo-Controlled Trial. Biological Psychiatry, 2018, 83, S127-S128.	1.3	0
164	177. Effects of Antipsychotic Medication on Brain Structure: Data From a Double-Blind, Randomized, Placebo-Controlled Trial. Biological Psychiatry, 2019, 85, S73.	1.3	0
165	178. Brain Network Biomarkers of Remitted Psychotic Depression. Biological Psychiatry, 2019, 85, S73-S74.	1.3	0
166	HEALTH-RELATED QUALITY OF LIFE IN REMITTED PSYCHOTIC DEPRESSION. American Journal of Geriatric Psychiatry, 2019, 27, S177-S178.	1.2	0
167	176. Sustaining Remission of Psychotic Depression: The Stop-PD II Study. Biological Psychiatry, 2019, 85, S72-S73.	1.3	0
168	Effects of Preexisting Psychotropic Medication Use on a Cohort of Patients with Ischemic Stroke Outcome. Stroke Research and Treatment, 2020, 2020, 1-8.	0.8	0
169	Combinatorial Pharmacogenomic Testing Improves Outcomes for Older Adults With Depression. Focus (American Psychiatric Publishing), 2021, 19, 76-85.	0.8	0
170	BENZODIAZEPINE RESPONSE. American Journal of Nursing, 2001, 101, 13.	0.4	0
171	Treating Depression and Psychosis. Medical Psychiatry, 2009, , 234-247.	0.2	0
172	Reply to "Can Long-Term Antidepressant Use Be Depressogenic?". Journal of Clinical Psychiatry, 1999, 60, 263-264.	2.2	0
173	An Introduction and My Vision for JCP. Journal of Clinical Psychopharmacology, 2021, 41, 1-2.	1.4	0
174	Psychopharmacology. Journal of Clinical Psychopharmacology, 2022, 42, 1-2.	1.4	0